Previous studies have shown that 17,19,21-tri-N-methyl-Aβ16-22 peptide (Aβ16-22m), and a peptide analogue containing α,α-disubsituted amino acids (ααAA) in the hydrophobic core domain of Aβ, termed AMY-1, effectively inhibited full-length Aβ aggregation in vitro. To investigate the amyloid-modifying effects of these agents in vivo, we injected these compounds into the hippocampus of 13-month-old amyloid precursor protein (APP) transgenic mice, a model of amyloid deposition. After 7 days, brain tissues were stained for immunohistochemistry to detect total Aβ and thioflavine-S (THIO-S) to measure Aβ compact plaques. Both diffuse Aβ deposits and compact amyloid plaques were significantly increased when injecting 0.3 nmol Aβ16-22m compared to the PBS vehicle. The amyloid aggregation-modifying peptide AMY-1 showed a slight reduction of Aβ deposition in the injection area at a dose of 0.3 nmol, but neuronal toxicity, measured by Fluoro-Jade and Nissl stains, appeared when higher doses (3 nmol) were tested. Our data indicate that, unlike observations reported in vitro, the Aβ16-22m increased deposition of Aβ in the brain of APP transgenic mice in vivo. Possible explanations for this outcome include unique influences of the brain environment and/or modification of Aβ production or clearance by the administered agent. The AMY-1 peptide showed a trend for reducing Aβ deposits, but led to toxicity at higher doses. These data emphasize the need for evaluating potential Aβ aggregation inhibitors with in vivo models of amyloid deposition before assuming they will have benefit in treating Alzheimer's disease patients.
INTRODUCTION
the Aβ primary sequence controls its self-assembly mechanisms. From mutagenesis studies of Aβ, it has been shown that the hydrophobic core, KLVFF, serves Alzheimer's disease (AD) can be at least partially characterized as a protein misfolding disease (16). Solu-as a key sequence in the self-assembly of Aβ (17, 33) . KLVFF peptide sequence forms amorphous aggregates, ble Aβ monomers aggregate into higher order assemblies (some of which may constitute the more toxic enti-do not form fibrils per se (33) , but is capable of binding to and inhibiting formations of Aβ fibrils. Thus, a num-ties) and over time aggregate into insoluble fibrils. It has been argued that one or more of these higher order Aβ ber of groups have investigated peptides related to the hydrophobic core of Aβ (residue 16-22, Lys-Leu-Val-assemblies leads to neuronal injury and is a critical step in the pathogenesis of AD (15, 20, 35, 36) . Therefore, in-Phe-Phe-Ala-Glu; KLVFFAE) as potential blockers of Aβ aggregation and fibrillogenesis. Their approach re-hibiting aggregation of Aβ has become a significant therapeutic approach for treatment of AD. Aβ peptide-lied on self-recognition of the hydrophobic core with inhibitor compounds and the adaptation of specific con-based inhibitors have been developed to block the critical process of Aβ assembly into oligomers or fibrils, formational changes of Aβ with their proposed inhibitors to limit toxicity. Soto and coworkers used the recog-presumably by interfering with the propagation of favorable interactions that stabilize these structures (6,12,13, nition sequence, but incorporated L-proline, due to its 'β-sheet breaking" capabilities, within the hydrophobic 21, 33) .
Aβ peptide-based mitigator design strategies have core of Aβ and found that their inhibitor was able to convert Aβ fibrils to amorphous aggregates and inhibit been derived from an increased understanding of how toxicity in vitro (2, 30, 31) . Murphy and colleagues methylated Aβ peptide region corresponding to Aβ16-22 domain (KLVFFAE; methylated at the L, F, and A (11,23,24) used a strategy where they designed peptides that bind to the hydrophobic core of Aβ and disrupt fi-residues, Aβ16-22m) ( Fig. 1B ). However, neither of these compounds has been tested in vivo to ascertain if their bril formation by altering the rate of aggregation. This increase in Aβ aggregation produced mature fibrils that antifibril characteristics were retained inside the brain. were nontoxic to PC12 cells.
MATERIALS AND METHODS

Recently some of us reported a compound (AMY-
Peptide Synthesis 1) ( Fig. 1A ) that contains α,α-disubstituted amino acids (ααAA) in the hydrophobic core of Aβ16-20 (KLVFF), AMY-1 was synthesized as previously reported (10) ( Fig. 1 
which blocked fibrillogenesis of full-length Aβ in vitro (9). Gordon and coworkers (12) reported a similar inhi-was synthesized using four equivalents of Fmoc amino acid and activation with PyAOP, and diisopropylethy-bition of full-length Aβ fibrillogenesis in vitro by an N- Table 1 . 1). A stepwise coupling of each amino acid was obtained using the standard solid phase Fmoc coupling Experimental Design chemistry. Each amino acid coupling was heated at 50°C. A double coupling of each N-methylated amino Transgenic Tg2576 APP mice (18) and nontransgenic littermates were obtained after breeding of Tg2576 APP acid residue and the N-terminal N-methylated amino acid residue was performed to maximize coupling mice with line 5.1?presenilin-1 (PS1) mice (8), which yielded four different genotypes: nontransgenic, trans-yields. Fmoc group deprotection was accomplished using Pip-DBU-DMF (5:2:93) for 5 min. Peptide cleavage genic APP, transgenic PS1, and doubly transgenic APP + PS1 mice. Animals were provided food and water ad from the solid support was performed using Reagent B (TFA/phenol/water/TIPS, 88:5:5:2) (29). Peptides were libitum and were kept on a 12-h light/dark cycle. They were group housed where feasible until surgery, after purified using reversed phase HPLC with linear gradients of 0.1% aqueous TFA in H 2 O (v/v) (buffer A) and which mice were singly housed until tissues were collected. 0.1% TFA in CH 3 CN (v/v) (buffer B). The molecular masses of the peptides were verified with MALDI-MS
The results presented here are from two cohorts of Abbott Laboratories, North Chicago, IL) and perfused intracardially with 25 ml of 0.9% sodium chloride and 50 ml of freshly prepared 4% paraformaldehyde, buffered to pH 7.4. The brains were collected and postfixed for 24 h in 4% paraformaldehyde. The brains were then cryoprotected by sequential 24-h incubations in 10%, 20%, and 30% sucrose. Frozen horizontal sections of 25-µm thickness were collected with a sliding microtome and stored at 4°C in Dulbecco's PBS buffer with sodium azide to prevent microbial growth.
Immunohistochemistry
Six sections were selected for free-floating immunohistochemistry to measure a) total Aβ deposition using a rabbit anti-Aβ serum at a concentration 1:10,000 (gen- Briefly, sections were placed in multisample staining tray and endogenous peroxidase blocked (10% methanol, 30% H 2 O 2 , in PBS). Tissue samples were then per-13-month-old mice (to produce sufficient sample sizes meabilized with lysine 0.2%, 1% Triton X-100 in PBS for statistical analysis). APP transgenic mice in the first solution, and incubated overnight in primary antibody. cohort were divided into three groups. Mice in group Sections were washed in PBS and then incubated in corone received intrahippocampal injections of AMY-1 (0.3 responding biotinylated secondary antibody (Vector Labonmol in 2 µl phosphate-buffered saline (PBS), pH 7.4; ratories, Burlingame, CA). The tissue was again washed group two received Aβ16-22m (0.3 nmol in 2 µl PBS); after a 2-h incubation period and treated with Vectasgroup three received PBS vehicle control (2 µl). Sample tin Elite ABC kit (Vector Laboratories) for enzyme size was four per group. For the second cohort, mice conjugation. Finally, sections were stained using 0.05% were injected with AMY-1 (3 nmol in 2 µl PBS, n = 6); diaminobenzidine and 0.3% H 2 O 2 (for CD45, 0.5% nick-Aβ 16-22m (0.3 nmol in 2 µl PBS, n = 7); PBS (2 µl) elous ammonium sulfate was added for color enhancecontrol (2 µl, n = 7), and additional nontransgenic mice ment). Tissue sections were mounted onto slides, dehywere injected with AMY-1 (3 nmol in 2 µl PBS, n = 3). drated, and coverslipped. Each immunochemical assay Surgical Procedure omitted some sections from the primary antibody incubation period to evaluate nonspecific reactivity of the On the day of surgery, the mice were weighed, anessecondary antibody. thetized with isoflurane, and placed in a stereotaxic apparatus (51603 dual manipulator laboratory standard;
Histology Stoelting, Wood Dale, IL). A midsagittal incision was A series of six sections 100 µm apart spanning the made to expose the cranium, and a burr hole was drilled site of injection were mounted on slides and stained with over the right hippocampus at the following coordinates: a) thioflavine-S (THIO-S, 1%; Sigma Aldrich, St. Louis, posterior, −2.7 mm; lateral, −2.5 mm, from bregma. A MO) to assess compact plaque deposition; b) cresyl vio-26-gauge needle attached to a 10-µl syringe (Hamilton, let (cohort 2 only; EM Science, Gibbstown, NJ); or c) Reno, NV) was lowered 3 mm ventral to bregma, and a Fluoro-Jade (cohort 2 only; Histo-Chem Inc., PO Box 2-µl injection was made over a 2-min period. The left 183, Jefferson, AR) to detect neuronal degeneration. For hemisphere was untreated to serve as an internal control THIO-S, the mounted/air-dried sections were rehydrated for individual differences in amyloid deposition among in H 2 O for 10 s, stained with Mayer's hematoxylin for the APP mice. The incision was cleaned with saline and 2 min, and then immersed in ammonia water for 30 s. closed with surgical staples.
The sections were then rinsed in three changes of water Tissue Preparation and incubated in 1% THIO-S for 10 min in the dark, rinsed rapidly in two changes of water, dehydrated One week after the surgery mice were overdosed with pentobarbital 100 mg/kg (Nembutal sodium solution;
through 75%, 100% ethanol, cleared in xylene for 5 min in each of three changes, and coverslipped with DPX mouse). All images were taken from the same location in all animals. Quantification of positive staining prod-microscopy mountant. Care was taken to minimize exposure of THIO-S or Fluoro-Jade sections to ambient uct (percent of area) surrounding and including the injection sites in the right hippocampus and the corre-light. Cresyl violet stain was performed by the method described previously by our laboratory (4) and Fluoro-sponding regions in the left hemisphere were determined using Image-Pro Plus (Media Cybernetics, Silver Jade was performed with the method described by Schmued (27) .
Springs, MD). Ratios of the right and left regions were calculated (to normalize for variability in amyloid depo-Image Analysis of Stained Sections sition between animals) and ANOVA statistical analysis was performed using StatView version 5.0.1 (SAS In-Stained sections were imaged using an Evolution MP digital camera mounted on an Olympus BX51 micro-stitute, Raleigh, NC).
To assess possible treatment-related differences, the scope at 100× final magnification (10× objective). Six horizontal brain sections (100 µm apart; every fourth measurements for either cortex or hippocampus of each subject were analyzed by ANOVA with StatView section) were taken from each animal and four nonoverlapping images near the site of injection from each of software version 5.0.1 (SAS Institute Inc.) followed by Fisher's least significant difference means comparisons. these sections were captured (24 measurements per rum raised against Aβ1-40 that we used for immunohistochemical staining and 6E10, a monoclonal mouse antihuman Aβ antibody, were used as primary antibodies. Horseradish peroxidase-conjugated goat-anti-rabbit and goat-anti-mouse antibodies were used as secondary antibody. ELISA procedures were performed as described previously by our laboratory (22) .
RESULTS
Intracranial Administration of N-Methylated Aβ Core Peptide (Aβ16-22m) Increased Aβ Deposition in the Injection Area
Immunohistochemistry revealed the distribution and amount of Aβ, both compact and diffuse, in cortex and hippocampus were similar to those previously described pared to the uninjected contralateral hippocampus (Fig.  2C ). There was no asymmetry in Aβ staining in mice receiving PBS vehicle control ( Fig. 2A, B ). AMY-1 ap-ELISA Assay peared to slightly decrease Aβ deposition in the injected AMY-1, Aβ16-22m, unmodified Aβ1-40 (positive side of the hippocampus (Fig. 2F ) compared to the unincontrol), unmodified Aβ12-28 (antigen control), and jected side ( Fig. 2E ) at a dose of 0.3 nmol. Quantifica-PBS (negative control) were dissolved in PBS and 250 tion of the percentage area of positive staining showed ng/well coated onto a microplate. The polyclonal antisethat the ratio of injected to uninjected hippocampi in mice receiving Aβ16-22m injections was significantly increased by 160% compared to mice treated with PBS vehicle (Fig. 3) . Although AMY-1 injections tended towards a reduction in Aβ immunostaining (−30%), this trend was not statistically significant compared to mice treated with PBS vehicle (the 0.3 nmol dose of AMY-1 was only tested in mice from cohort 1) ( Fig. 3 ). THIO-S staining was used to label compact fibrillar amyloid plaques. The THIO-S staining regional distribution was similar to immunohistochemistry for Aβ, but the area of THIO-S staining was substantially less than Aβ immunostaining as diffuse Aβ deposits were not labeled. The Aβ16-22m increased THIO-S stained plaques in the injected hippocampus ( Fig. 4D) relative to the contralateral hippocampal regions (Fig. 4C) . No asymmetry was found in the vehicle control group (Fig. 4B ). AMY-1 showed a trend towards reduction on the injected side similar to the results with immunohistochem- trend to reduce compact plaque deposits (Fig. 5 ). Be-Anti-rabbit (1:1,000) and anti-mouse (1:8,000) IgG-HRP were cause of the trends observed with AMY-1 in cohort 1, used as secondary antibodies to detected anti-Aβ40 antibody and 6E10, respectively.
we increased the dosage to 3 nmol per injection in co- hort 2, but left the dose for Aβ16-22m the same to con-react with N-terminal epitopes in Aβ). Signals against Aβ16-22m, AMY-1, and Aβ12-28 peptide were identi-firm this observation.
cal to the signal with PBS, indicating no specific associ-ELISA Assay Rules Out Cross-Reactivity With Anti-Aβ ation of the antibodies with these peptides. These data Antisera as the Explanation for Increased argue that the increased Aβ deposition after Aβ16-22m Immunostaining With Aβ16-22m Injections injection was not an artifact of antiserum cross-reactivity with the injected agent. One possible explanation for the increased Aβ immunostaining in Figures 2 and 3 is that the antiserum used Microglial Activation Is Increased in Mice Treated to detect Aβ might also react with the peptides used to With High Dose AMY-1 modulate amyloid aggregation. To test whether the Aβ16-22m or AMY-1 peptides reacted with the anti-Aβ CD45, a commonly used marker for microglial activation, is normally expressed on microglia around amy-antiserum used for immunostaining, we performed an ELISA, coating the plates with various peptides and loid deposits in aged APP transgenic mice and increases slightly surrounding the area of injection under all con-probing the plates with the rabbit antiserum against Aβ and a mouse monoclonal anti-Aβ antibody 6E10. Figure  ditions (Fig. 7A-D) . In the mice treated in cohort 2, CD45 expression increased dramatically in the dentate 6 shows that the rabbit antiserum and 6E10 only detect intact Aβ1-40 (prior work demonstrated both antibodies gyrus around the injection area in mice receiving 3 nmol AMY-1 (Fig. 7F) . Quantitative analysis showed a 2.5fold increase in the ratio of injected side to uninjected side in mice treated with AMY-1 at a dose of 3 nmol compared to those mice receiving PBS vehicle (Fig. 8) . This observation led us to investigate what might be a cause for this increase.
Neurotoxicity Is Induced in Mice Treated With High-Dose AMY-1
Nissl staining of sections through the injection site of mice in cohort 2 revealed thinning of the dentate gyrus granule cell layer as a result of 3 nmol AMY-1 injection (Fig. 9 ). In the transgenic mice, the damage appeared extensive, with an entire blade of the dentate granule cell layer impacted, and pyramidal neurons in the CA3/ 4 also showing damage (Fig. 9H) . In nontransgenic mice injected with the same dose of AMY-1, the damage was 
In all cases, the cells remained intact in the uninjected
Mice were received PBS control (A, B); Aβ16-22m (0.3 nmol) side (Fig. 9G, I) . There was no damage found in mice To estimate the extent of neurotoxicity, we stained a series of sections with Fluoro-Jade, which labels dead or dying cells (Fig. 10) . We also stained sections from nontransgenic mice receiving the high-dose AMY-1 with Fluoro-Jade and observed a similar but smaller trend for increased Fluoro-Jade staining (Fig. 10G-I) . Quantitative analysis of the area of damaged neurons (acetyl-LPFFD-amide)], Chacon et al. (5) significantly increased spatial learning acquisition and reduce cogni-induced by 3 nmol of AMY-1 injection with Fluoro-Jade showed that there was a significant destruction of cells tive impairment and cerebral damage in transgenic mice. iAβ5p also blocked the hypertrophic response of astrog-in dentate gyrus and CA4 region in APP transgenic mice compared to PBS vehicle (Fig. 11 ). lia to Aβ, an index of inflammation. Despite this success, to date few compounds have been shown to offer DISCUSSION a beneficial effect in vivo in transgenic mice model of AD (25) . In the past decade, many short synthetic Aβ hydrophobic core domain peptide-based inhibitors have been
In this study, we tested a recently designed novel peptide analogue containing α,α-disubstituted amino reported to inhibit Aβ fibrillogenesis (1, 6, 12, 28, 33) and amyloid neurotoxicity in vitro (1, 6) . acids (ααAA) in the central hydrophobic core domain of Aβ (residues 16-20; KLVFF), termed AMY-1. AMY-Soto and colleagues designed a β-sheet breaker peptide, iAβ5 (LPFFD), related to the hydrophobic core of 1 was previously demonstrated to inhibit the formation of mature Aβ fibrils in vitro (9). For comparison pur-Aβ that considerably inhibited Aβ fibril formation in vitro and in vivo for both neurotoxic isoforms of Aβ poses, we tested another peptide-based inhibitor with Nmethyl amino acids in alternating positions in the hydro- (2, 30, 31) . Using this same peptide, with a slight modification to protect it against proteolytic degredation [iAβ5p phobic core domain of Aβ (Aβ16-22m) that also was production might ensue due to increased substrate availability. A second possibility is decreased cleavage of Aβ by the endoproteases known to degrade the Aβ peptide. Neprilysin, endothelin converting enzyme, and insulysin, all proposed to be endogenous amyloid cleaving proteases, hydrolyze peptide bonds within this domain. If the Aβ16-22m peptide was bound to these enzymes it could reduce amyloid clearance either by enzyme inhibition or substrate level competition. Either of these actions-increased production or diminished clearance of Aβ-could account for increased amyloid deposition in vivo by agents that inhibit fibrillogenesis in vitro.
A third option is that the brain microenvironment modifies the actions of the agents from that observed in vitro. It is possible that the β-strands of Aβ16-22m oligomers and/or fibrils.
AMY-1 is also designed to work by binding to Aβ through one hydrogen-bonding face and subsequently reported to inhibit the fibrillogenesis of Aβ in vitro and further shown to disassemble preformed Aβ fibrils (12). blocking further assembly by exposing a nonhydrogen bonding face through the use of an alternating α,α- Table 1 summarizes the results of peptide synthesis and characterization.
amino acid/L-amino acid instead of N-methylation. When the AMY-1 compound was administrated into the Aβ16-22 is among the shortest fibril-forming Aβ fragments (3, 19, 34) and readily aggregates and forms brain of APP transgenic mice at a dose of 0.3 nmol, a trend towards a similar action as was shown in vitro fibrils in vitro (32,33). Unexpectedly, the Aβ16-22m not only failed to inhibit aggregation of Aβ when adminis-was obtained (9). Both diffuse and compact Aβ deposits trended towards reduction (approximately 30%) in the tered in vivo, but resulted in an increase in Aβ deposits at equimolar concentrations (Figs. 2-5).
injection area but failed to reach significance compared to vehicle-treated animals. In an attempt to increase the There are at least three possible explanations for this outcome. First is an artifactual increase in immunohisto-effect size we increased the dose to 3 nmol and increased the sample size. However, neuronal cell death chemical signal caused by the peptide cross-reacting with the antisera used to detect Aβ deposits. To address occurred in response to this dose in APP transgenic mice, and to a lesser extent in nontransgenic mice. In this possibility, an ELISA assay was performed. Our data showed that the antiserum only bound the full-APP mice this was associated with increased microglial activation surrounding the damaged neurons. These data length Aβ but not Aβ16-22m, AMY-1, or an Aβ12-28 fragment that contained the 16-22 epitope (Fig. 6 ). This suggest that there is some inherent toxicity with this dose of AMY-1 that is exacerbated in the APP mice. was consistent with our earlier work demonstrating that the predominant epitope for this antiserum was in the N-This is consistent with AMY-1 cytotoxicity in rat PC12 pheochromacytoma cell lines and primary cortical neu-terminal domain (1-10) of the Aβ peptide (7). Furthermore, the increase in THIO-S staining would be unlikely rons in vitro (data not shown). AMY-1 reduces cell viability ϳ40% at a concentration of 50 µM compared to to result from cross-reactivity with the injected peptide.
Thus, it appears that the injection of Aβ16-22m some-untreated cell controls. However, AMY-1 in the presence of Aβ solutions (5-25 µM) has a protective mecha-how caused a rapid increase in the deposition of endogenous Aβ peptide. nism, reducing cytotoxicity in vitro >90% only (data not shown). Thus, the toxicity of AMY-1 is likely due to A second plausible explanation is an indirect effect of the peptide on Aβ metabolism. The amino acid do-the amphipathic nature of this peptide with its highly hydrophobic N-terminus and a highly charged C-termi-main of Aβ16-22m is rich with cleavage sites for known brain proteases. First the α-secretase site is within this nus. Future designs of ααAA Aβ aggregation mitigators will have less charge and use nonionic solubulizing ele-domain. If Aβ16-22m inhibited α-secretase, a compensatory increase in β-secretase processing of APP and Aβ ments. APP transgenic model of amyloid deposition. Although
